
icon
-
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
-
How collaboration can enhance your science career
-
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Innovation fueled by compassion
-
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
-
In neuroscience, “an inflection point in knowledge and technology”
-
A shared mission to take on the “impossible” in cancer research
-
The art of drug design in a technological age
-
Stopping this coronavirus – and the next one
-
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)